New antiplatelet therapies in development

American Journal of Health-System Pharmacy

Volumn 65, Issue 13 SUPPL. 5, 2008, Pages

  Price, Matthew J ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

Aspirin; AZD6140; Cangrelor; Cardiovascular diseases; Clopidogrel; Dosage; Mechanism of action; Pharmacokinetics; Platelet aggregation inhibitors; Prasugrel; Product development; Thienopyridines; Toxicity; TRA SCH 530348

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; PRASUGREL; THIENOPYRIDINE DERIVATIVE; THROMBIN; THROMBIN INHIBITOR; TICAGRELOR; TRA SCH 530348;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG SAFETY; DYSPNEA; HEART INFARCTION; HUMAN; INCIDENCE; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STANDARD; STEADY STATE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE;

EID: 46049102411     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080157     Document Type: Conference Paper

References (24)

1. Krasopoulous G, Brister SJ, Beattie WS et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008; 336:195-8.
2. Quick AJ. Salicylates and bleeding: the aspiring tolerance test. Am J Med Sci. 1966; 252:265-9.
3. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot study including 180 post-stroke patients. Thromb Res. 1993; 71:397-403.
4. Gum PA, Kottke-Marchant K, Welsh PA et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003; 41:961-5.
5. Järemo P, Lindahl TL, Fransson SG et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med. 2002; 252:233-8.
6. Müller I, Besta F, Schulz C et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003; 89:783-7.
7. Gurbel PA, Bliden KP, Hiatt BL et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003; 107:2908-13.
8. Serebruany VL, Steinhubl SR, Berger PB et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005; 45:246-51.
9. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007; 49:1505-16.
10. Hocholzer W, Trenk D, Frund D et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005; 111:2560-4.
11. Buonamici P, Marcucci R, Migliorini A et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007; 49:2312-7.
12. Price MJ, Endemann S, Gollapudi RR et al. Prognostic significance of postclopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008 Feb 10 [Epub ahead of print].
13. Brandt JT, Payne CD, Wiviott SD et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007; 153:66.e9-16.
14. 12 antagonist, with clopidogrel in percutaneous coronary intervention. Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO) - TIMI 26 Trial. Circulation. 2005; 111:3366-73.
15. Price MJ, Coleman JL, Steinhubl SR et al. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol. 2006; 98:681-4.
16. 12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006; 27:1038-47.
17. Storey RF, Husted S, Harrington RA et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007; 50:1852-6.
18. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357:2001-15.
19. Cannon CP, Husted S, Harrington RA et al; DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007; 50:1844-51.
20. O'Donoghue M, Wiviott SD. Clopidogrel response variability and future therapies. Clopidogrel: Does one size fit all? Circulation. 2006; 114:e600-6.
21. 12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J. 2006; 151:689.e1-689.e10.
22. A Clinical Trial to Demonstrate the Efficacy of Cangrelor. www.clinicaltrials.gov/ct2/show/NCT00305162?term=cangrelor&rank=3 (accessed 2008 Jan 14).
23. Drug Development Technology: TRA-SCH-530348 - A novel oral antiplatelet agent. www.drugdevelopment-technology.com/project_printable.asp?ProjectID=4020 (accessed 2008 Jan 14).
24. Moliterno DJ, Becker RC, Jennings LK et al; TRA-PCI Study Investigators. Results of a multinational randomized, double-blind, placebo-controlled study of a novel thrombin receptor antagonist (SCH 530348) in percutaneous coronary intervention. Presented at the 56th Annual Scientific Session of the American College of Cardiology; March 24-27, 2007; New Orleans, LA.